Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368744 | 1.00 | BRD4 (0.45) | BRD4PIK3C3KDM5AIGF1RCDK2 | |
| SCHEMBL30578263 | 0.74 | BRD4 (0.41) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL2619221 | 0.74 | BRD4 (0.45) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL1019760 | 0.74 | NFATC1 (0.44) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL23148015 | 0.74 | NUDT1 (0.43) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL2628872 | 0.74 | BRD4 (0.41) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL30554075 | 0.74 | NFATC1 (0.44) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL15926855 | 0.74 | BRD4 (0.41) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL529739 | 0.74 | AHR (0.52) | BRD4PIK3C3IGF1RCDK2DYRK1B | |
| SCHEMBL1472503 | 0.74 | BRD4 (0.39) | BRD4PIK3C3IGF1RCDK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440573-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | Mydecine Innovations Group Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-06-20 | — | — | US | disclosed |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-03-28 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | BRD4 972/4885PIK3C3 3765/4885KDM5A 885/4885 |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | BRD4 972/4885PIK3C3 3765/4885KDM5A 885/4885 |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | BRD4 1123/4885PIK3C3 3449/4885KDM5A 619/4885 |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | PSAP, ABCG2, PSAT1 | BRD4 2602/4885PIK3C3 4477/4885KDM5A 4011/4885 |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | BRD4 1123/4885PIK3C3 3449/4885KDM5A 619/4885 |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | BRD4 1123/4885PIK3C3 3449/4885KDM5A 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.